{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:40:00Z","timestamp":1792834800415,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.resinv.2026.101513","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:58:00Z","timestamp":1789466280000},"page":"101513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nintedanib for progressive pulmonary fibrosis associated with sarcoidosis: a retrospective preliminary observational report"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2222-0683","authenticated-orcid":false,"given":"Toru","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1470-2460","authenticated-orcid":false,"given":"Masaki","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryouta","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayoko","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunobu","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101513_bib1","first-page":"89","volume":"22","year":"2007","journal-title":"Jpn J Sarcoidosis Other Granulomatous Disord"},{"key":"10.1016\/j.resinv.2026.101513_bib2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.resinv.2019.11.003","article-title":"Characteristics of 68 patients with clinically proven sarcoidosis based on the Japan society of sarcoidosis and other granulomatous disorders 2015 criteria","volume":"58","author":"Yamanouchi","year":"2020","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2026.101513_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1567334","article-title":"Clinical characteristics of patients with pulmonary sarcoidosis treated with systemic steroids in Japan","volume":"12","author":"Sawahata","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2026.101513_bib4","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101513_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12931-022-02094-7","article-title":"Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis","volume":"23","author":"Schimmelpennink","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2026.101513_bib6","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.2169\/internalmedicine.51.7394","article-title":"A case of combined sarcoidosis and usual interstitial pneumonia","volume":"51","author":"Tachibana","year":"2012","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2026.101513_bib7","first-page":"1","article-title":"Poor outcome and mortality in patients with lower lung-dominant sarcoidosis","volume":"2023","author":"Tachibana","year":"2023","journal-title":"Canadian Res J"},{"key":"10.1016\/j.resinv.2026.101513_bib8","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.resinv.2026.101513_bib9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101513_bib10","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101513_bib11","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101513_bib12","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101513_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2026.101513_bib14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13023-020-01546-x","article-title":"Clinical significance of serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis","volume":"15","author":"Katayama","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.resinv.2026.101513_bib15","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.2169\/internalmedicine.3853-19","article-title":"Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: the clinical course and serum levels of anti-granulocyte-macrophage colony-stimulating factor autoantibody","volume":"59","author":"Arai","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2026.101513_bib16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101513_bib17","series-title":"Common terminology criteria for adverse events (CTCAE). Version 5.0","year":"2017"},{"key":"10.1016\/j.resinv.2026.101513_bib18","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232558","article-title":"Fleischner society: glossary of terms for thoracic imaging","volume":"310","author":"Bankier","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.resinv.2026.101513_bib19","article-title":"Imaging findings of fibrosis in pulmonary sarcoidosis","volume":"39","author":"Sawahata","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.resinv.2026.101513_bib20","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.rmed.2018.08.008","article-title":"Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?","volume":"144","author":"Collins","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2026.101513_bib21","doi-asserted-by":"crossref","first-page":"7914","DOI":"10.3390\/jcm14227914","article-title":"Effectiveness of a 5-hydroxytryptamine type 3 receptor antagonist for treating nintedanib-induced diarrhea: a prospective observational study","volume":"14","author":"Arai","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2026.101513_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28403","article-title":"Nintedanib in chronic fibrosing interstitial lung diseases. A case series. A case series","volume":"10","author":"Garc\u00eda Sevila","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.resinv.2026.101513_bib23","article-title":"Pirfenidone for progressive fibrotic sarcoidosis (PIRFS): results of a double blind placebo controlled pilot study","volume":"203","author":"Baughman","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101513_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02571-2021","article-title":"Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry","volume":"60","author":"Hambly","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101513_bib25","article-title":"The role of diverse immune cells in sarcoidosis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101513_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0178-2022","article-title":"Immune mechanisms in fibrotic pulmonary sarcoidosis","volume":"31","author":"Weeratunga","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2026.101513_bib27","article-title":"Pulmonary fibrosis in sarcoidosis","volume":"40","author":"Asif","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.resinv.2026.101513_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1164\/rccm.200912-1855OC","article-title":"Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis","volume":"181","author":"Lockstone","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101513_bib29","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3390\/cells11040664","article-title":"Comparative analysis of gene expression in fibroblastic foci in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis","volume":"11","author":"Kamp","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.resinv.2026.101513_bib30","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101513_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1445923","article-title":"Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?","volume":"15","author":"B\u0105czek","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.resinv.2026.101513_bib32","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2147\/DDDT.S288369","article-title":"The effect of nintedanib on T-cell activation, subsets and functions","volume":"15","author":"Ubieta","year":"2021","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.resinv.2026.101513_bib33","article-title":"Atypical CT findings of pulmonary sarcoidosis: a case report","volume":"97","author":"Lee","year":"2018","journal-title":"Med (Baltim)"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526001474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526001474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:29:20Z","timestamp":1792834160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534526001474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2212534526001474"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101513","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nintedanib for progressive pulmonary fibrosis associated with sarcoidosis: a retrospective preliminary observational report","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}],"article-number":"101513"}}